Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7049665 in autoimmune hepatitis
NCT04790916Phase 2Terminated
- Sponsor
- Roche
- Start
- Apr 2021
- Primary completion
- Nov 2021
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of melredableukin alfa in autoimmune hepatitis (AIH) (3 arms), sponsored by Roche. Primary endpoint: Time to Relapse for RO7049665 7.5 mg Versus Placebo up to 25 months. Started Apr 2021; status: terminated.
02
Drugs
melredableukin alfa
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NCT04790916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790916.